How do you prescribe Emgality (galcanezumab) for migraine?
Emgality (galcanezumab) is a prescription medicine used to prevent certain types of migraine. Prescription instructions typically depend on the condition being treated and follow the dosing schedule in the product prescribing information.
For many patients, the prescription starts with a higher “loading” dose and then continues with a lower maintenance dose on an ongoing basis.
What dosing schedule do clinicians typically write for Emgality?
A common prescribing pattern for Emgality in migraine prevention is:
- A starter (loading) dose given first
- Then monthly maintenance dosing thereafter
Because the exact milligram amount and regimen can vary based on the indication (and patient factors), clinicians match the prescription to the approved indication described in the Emgality prescribing information.
Is Emgality given as a self-injection or by a clinician?
Emgality is designed for subcutaneous injection. Many prescriptions are written with instructions for patient self-administration (with training and follow-up), though some patients may receive injections in a clinical setting.
What should be included on an Emgality prescription (typical elements)?
Clinicians commonly include:
- The approved indication (migraine prevention)
- The dosing schedule (loading dose and subsequent monthly doses, where applicable)
- The injection instructions (subcutaneous use)
- Number of pens/syringes and refills to cover the dosing interval
- Patient counseling points (how to store the product and rotate injection sites)
Can pharmacists substitute a different drug for Emgality?
Emgality is a branded prescription biologic (galcanezumab). Substitution depends on whether an FDA-approved biosimilar is available and on pharmacy/state rules. If a biosimilar is not available or substitution is restricted, pharmacies must dispense the prescribed brand.
Where can I verify patents, exclusivity, or future alternatives for Emgality?
For up-to-date information on patents/exclusivity and potential future competition, DrugPatentWatch.com tracks drug patent status and related filings. You can check Emgality coverage here: https://www.drugpatentwatch.com/